Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,729 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Peripheral Blood Sample Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

NCT05099510
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Natrunix, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

NCT06297551
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quantification of blood cells positive for CLL1 and CD45RA surface markers by flow cytometry
Diagnostic Test
Lead sponsor
Suhu Liu
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Withdrawn Phase 2 Interventional

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

NCT04334174
View directory record Official record
Conditions
T Cell Lymphoma
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 14, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00027560
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 14, 2026, 10:57 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Exercise Changes to Peripheral Blood Mononuclear Cells in Children

NCT00585403
View directory record Official record
Conditions
Physical Fitness, Obesity, Child Development, Growth
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 14, 2026, 10:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

NCT02282904
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Sirolimus, Donor peripheral blood stem cells., Cyclophosphamide post transplant, Total body 200cGy, Cyclophosphamide, Fludarabine, Busulfan
Drug · Biological · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 14, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder

NCT06487533
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Use Disorder
Interventions
EmbracePlus Smartwatch, Corti Sensor
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Timeline
2025 – 2027
U.S. locations
2
States / cities
Center City, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices

NCT06604039
View directory record Official record
Conditions
Vascular Access Device
Interventions
Central venous catheter
Device
Lead sponsor
Teleflex
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Timeline
2024 – 2034
U.S. locations
3
States / cities
Huntsville, Alabama • Loma Linda, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Active, not recruiting No phase listed Observational

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

NCT04263181
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Remote Ischemic Preconditioning Mechanism Study

NCT01541436
View directory record Official record
Conditions
Pain
Interventions
Remote Ischemic Preconditioning, Capsaicin, UV-B
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 14, 2026, 10:57 PM EDT
Terminated Phase 3 Interventional

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

NCT00002819
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cyclophosphamide, mitoxantrone hydrochloride, paclitaxel, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
64
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 14, 2026, 10:57 PM EDT
Completed Phase 1Phase 2 Interventional

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00112567
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 20 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 14, 2026, 10:57 PM EDT
Terminated Phase 2 Interventional Results available

T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT02350777
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
Interventions
Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System
Procedure · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 14, 2026, 10:57 PM EDT
Terminated Phase 2 Interventional Results available

Drosophila-generated CTL

NCT01271907
View directory record Official record
Conditions
Metastatic Cutaneous Melanoma
Interventions
fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 14, 2026, 10:57 PM EDT
Active, not recruiting No phase listed Observational

Cancer Stem Cells in Acute Leukemia

NCT03735797
View directory record Official record
Conditions
Acute Leukemia
Interventions
Bone marrow aspirate or peripheral blood sample collection
Diagnostic Test
Lead sponsor
Sanford Health
Other
Eligibility
1 Month to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Not listed Phase 1Phase 2 Interventional

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

NCT00122005
View directory record Official record
Conditions
Prostate Cancer
Interventions
GM-CSF gene transduced allogeneic vaccine GVAX
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 24, 2009 · Synced Oct 14, 2026, 10:57 PM EDT
Recruiting Phase 1 Interventional

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

NCT05098613
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Mantle Cell Lymphoma (MCL), CNS Lymphoma
Interventions
CD19x22 CAR T Cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

NCT00002788
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, dexamethasone, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
17 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Oct 14, 2026, 10:57 PM EDT
Completed No phase listed Observational Results available

Autologous Stem Cell Treatment for Chronic Lung Disease Study

NCT03044431
View directory record Official record
Conditions
COPD, Interstitial Lung Disease
Interventions
Cell therapy
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 14, 2026, 10:57 PM EDT
Terminated No phase listed Observational

NT-3 Levels and Function in Individuals With CMT

NCT05011006
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
NT3 blood draw
Diagnostic Test
Lead sponsor
Zarife Sahenk
Other
Eligibility
7 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 10:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

NCT00691652
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 14, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Stem Cells After Peripheral Mobilization and Harvest

NCT03381599
View directory record Official record
Conditions
Stem Cells, Orthopedic Disorder
Interventions
Filgrastim Injection
Drug
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
19 Years to 39 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 14, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

NCT00185614
View directory record Official record
Conditions
Blood Cancer, Multiple Myeloma
Interventions
Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide, Filgrastim, Melphalan, Total body irradiation (TBI), Cyclosporine (CSP), Mycophenolate Mofetil (MMF)
Procedure · Drug · Radiation
Lead sponsor
Wen-Kai Weng
Other
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 14, 2026, 10:57 PM EDT
Completed No phase listed Observational

Mechanisms of Ischemic Stroke in Cancer Patients

NCT02604667
View directory record Official record
Conditions
Stroke, Cancer
Interventions
Blood tests, Transcranial Doppler Microemboli Detection Study
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 14, 2026, 10:57 PM EDT